Loading...
OTCM
CYDY
Market cap404mUSD
Dec 05, Last price  
0.32USD
1D
0.00%
1Q
1.14%
Jan 2017
-52.25%
IPO
-84.76%
Name

Cytodyn Inc

Chart & Performance

D1W1MN
OTCM:CYDY chart
P/E
107.88
P/S
—
EPS
0.00
Div Yield, %
—
Shrs. gr., 5y
24.17%
Rev. gr., 5y
%
Revenues
-6m
000005,786-25,987000000000266,00000-5,916,000
Net income
4m
P
-1,489,700-2,610,070-1,193,684-1,572,804-3,736,944-3,741,137-7,492,802-9,568,301-12,431,413-25,926,713-25,703,612-25,763,801-48,458,746-56,186,660-141,783,223-174,018,000-288,163,000-79,824,000-49,841,0003,745,000
CFO
-9m
L-20.19%
-602,074-935,090-473,308-1,287,005-2,146,410-1,821,417-4,391,095-3,392,933-7,386,943-12,016,858-24,810,651-26,732,468-29,897,971-50,466,164-68,803,615-117,573,000-77,723,000-25,110,000-10,982,000-8,765,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (“COVID-19”). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
URL
https://www.cytodyn.com/
IPO date
Nov 17, 2005
Employees
23
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑052024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑052016‑05
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT